We are really looking forward to hosting an IRDG members visit to Helsinn Pharmaceuticals Centre of Excellence in Research & Development this November.
Helsinn, a privately owned pharmaceutical company, has established a Centre of Excellence in Research and Development for Oral Solid Dosage (OSD) at its Dublin facility, Helsinn Birex Pharmaceuticals. Helsinn’s core business is the in-licensing of late stage pharmaceutical compounds in therapeutic niche areas for development and subsequent commercial manufacture and distribution. The company is primarily active in oncology supportive care, anti-inflammatory and gastrointestinal treatments. The investment was part of Helsinn’s strategic decision to strengthen its in-house development capabilities. The Helsinn investment has established the Irish operation as the centre of knowledge and learning for OSD products in the Helsinn Group, and the launch site for new products within its portfolio. This investment puts the Irish operation at the core of Helsinn’s R&D activities.
From its 8000 sq m facility at Damastown, Dublin 15, Helsinn Birex Pharmaceuticals Ltd manages global supply of drug products for the Swiss based Helsinn Group, and performs Chemistry, Manufacturing Controls (CMC) development of late stage oral dosage pipeline products to support regulatory approval and market launch. Since commencing development activities in 2010 it has received new drug approvals by the European and US regulators as well as many other agencies worldwide.
What you will learn
During this visit Helsinn will present its business model based on Licensing, Development and Commercialization, and share insights into some particular aspects of pharmaceutical development based on experiences to date through a real world case study, which includes a collaboration with an Irish SME on novel packaging technology.
Please join the waiting list if the event is booked out. Spaces often become available at a later stage due to changes in people’s diaries.